



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Cardiology*

**Manuscript NO:** 68591

**Title:** Fondaparinux: A cornerstone drug in acute coronary syndromes

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03846820

**Position:** Editorial Board

**Academic degree:** FACC, FESC, MD

**Professional title:** Academic Research, Assistant Professor, Doctor

**Reviewer's Country/Territory:** Netherlands

**Author's Country/Territory:** India

**Manuscript submission date:** 2021-05-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-06-10 05:48

**Reviewer performed review:** 2021-06-10 09:23

**Review time:** 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

statements

Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

Dear authors, The paper represents the review article which is literally a systematic review that focused on fondaparinux in acute coronary syndrome. The article is written with the acceptable English-speaking adduction of the arguments. The article is sufficiently novel and very interesting to warrant publication. All the key elements are presented and described clearly. The most discussable options in the article are: 1. Would you please kindly correct all your typos and grammar errors throughout the manuscript. 2. The paper is built as a systematic review but would you please kindly write down a sort of Introduction with a clear objective. 3. Please harmonize the paper in the sense of what you are writing about. What is the idea of the subtitle “antithrombotic therapy”? Would you talk about antiplatelet drugs as well? It looks like your review about anticoagulant treatment exceptionally! Please, be focused on the topic. 4. It would help if you had more remarks about pathogenesis in your introduction to adequately justify the need for anticoagulants, maybe with a scheme. I see your figure 1, but can you upgrade it to understand why fondaparinux is essential. 5. What is that supposed to mean when you call fondaparinux a new anticoagulant? It is not new already for years, even decades. Please, mention the history of this drug in the article. It must be clear for a reader what is the clinical value of this drug today. 6. There must be a paragraph with an analysis of the international guidelines separately. Please, justify why guidelines recommend fondaparinux only in specific clinical scenarios. In table 10, you don't have any recent guidelines. But there are a few of them with a reconsidered vision on fondaparinux. 7. Tables: there is no summarized value of fondaparinux. I would strongly recommend you make a table merging and matching the performance of fondaparinux in the different studies as a sort of the summary ideally with all the prons



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

and cons (including “negative”/ “alarming” outcomes - I am about bleeding, first of all).  
8. Figures 3 and 4 are not readable. I would recommend you correcting the format for the Journal. 9. The general impression is that your analysis is slightly outdated. Please provide a reader with up-to-date information, including all the remarks and substudies in the field. Some of your current points are from the age of 2002-2007, like nothing happened after that.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Cardiology

**Manuscript NO:** 68591

**Title:** Fondaparinux in Acute Coronary Syndromes

**Reviewer's code:** 03846820

**Position:** Editorial Board

**Academic degree:** FACC, MD

**Professional title:** Academic Research, Assistant Professor, Doctor

**Reviewer's Country/Territory:** Netherlands

**Author's Country/Territory:** India

**Manuscript submission date:** 2021-05-27

**Reviewer chosen by:** Yun-Xiaojian Wu

**Reviewer accepted review:** 2021-09-05 10:28

**Reviewer performed review:** 2021-09-05 10:39

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

Dear authors, Thank you very much for your efforts to improve the paper. I have some



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

suggestions as follows: 1) I did not find any figures or tables in the submitted documents. 2) Your language requires some brushing-up. 3) The introduction has neither any justification of your topic not objective yet. 4) What is that supposed to mean “a newer anticoagulant”?! 5) Please, use the international definitions for all the conditions and medications. “Antithrombotic” must be deciphered. 6) It looks very raw and superficial at the moment. Would you please elaborate on the content, including options related to the international guidelines.